A new research paper was published in Volume 16 of Oncotarget on July 25, 2025, titled "Dissecting the functional differences and clinical features of...
Vous n'êtes pas connecté
- NEWS.MEDICAL.NET - A la Une - 11/Aug 17:13
RSPO2 gene identified as key driver in metastatic prostate cancer
A new research paper was published in Volume 16 of Oncotarget on July 25, 2025, titled "Dissecting the functional differences and clinical features of R-spondin family members in metastatic prostate cancer."
Articles similaires
New gene linked to aggressive, treatment-resistant prostate cancer
oncologynews.com.au - 21/Aug 04:31
A new research paper was published in Volume 16 of Oncotarget on July 25, 2025, titled “Dissecting the functional differences and clinical...
FDA-approved MI cancer seek test enhances tumour profiling for precision oncology
oncologynews.com.au - 22/Aug 00:34
A new research paper was published in Volume 16 of Oncotarget on August 13, 2025, titled “Clinical and analytical validation of MI Cancer Seek®,...
New compound disrupts survival pathways in aromatase inhibitor-resistant breast cancer cells
oncologynews.com.au - 23/Aug 01:07
A new research paper was published in Volume 16 of Oncotarget on July 29, 2025, titled PCAIs stimulate MAPK, PI3K/AKT pathways and ROS-mediated...
Study finds link between epigenetic aging and colorectal cancer risk in postmenopausal women
news.medical.net - 19/Aug 14:13
A new research paper was published in Volume 17, Issue 7 of Aging (Aging-US) on July 7, 2025, titled "Epigenetic age and accelerated aging phenotypes:...
Caris Life Sciences demonstrates scientific rigor with clinical validation of US FDA approved MI Cancer Seek
pharmabiz.com - 18/Aug 11:12
Caris Life Sciences, a leading, patient─centric, next─generation AI TechBio company and precision medicine pioneer, has published a study in...
Caris Life Sciences demonstrates scientific rigor with clinical validation of US FDA approved MI Cancer Seek
pharmabiz.com - 18/Aug 11:12
Caris Life Sciences, a leading, patient─centric, next─generation AI TechBio company and precision medicine pioneer, has published a study in...
Halda Therapeutics Receives FDA Fast Track Designation for HLD-0915 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
drugs.com - 14/Aug 06:08
NEW HAVEN, CT, August 14, 2025 — Halda Therapeutics, a clinical-stage biotechnology company developing a novel class of therapies called...
Les derniers communiqués
-
Evergreen Elevate Heads to Australia to Empower MSPs with Valuable Strategies and Insights on Better M&A Practices
Evergreen Elevate - 29/07/2025